Anuh Pharma Ltd (ANUHPHR) — shareholding pattern, promoter holding, financials and share price
About Anuh Pharma Ltd (ANUHPHR)
Anuh Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ANUHPHR and on the BSE under scrip code 506260. Its ISIN is INE489G01022.
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals [1]
Anuh Pharma Limited is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and bulk drugs, prominently serving the antibiotics, erythromycin salts, and chloramphenicol market segments.
Recently, Anuh Pharma has expanded its production capacity by commissioning an additional intermediate block, enhancing its capability to produce APIs and meet growing market demands.
Listed peers in Pharmaceuticals: Shree Ganesh Remedies Ltd, Hexagon Nutrition Ltd, Remus Pharmaceuticals Ltd, Sigachi Industries Ltd, Anlon Healthcare Ltd, Amanta Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹78.74 a share on 10 Jul 2026, Anuh Pharma Ltd (ANUHPHR) was valued at a price-to-earnings ratio of 19.23x against an industry P/E of 36.41x and a price-to-book of 2.42x on a book value of ₹32.53 per share as of Mar 2025. Solomo computes return on equity of 12.59% and return on capital employed of 16.24% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 19.23x
- Industry P/E
- 36.41x
- P/B
- 2.42x
- EPS (TTM)
- ₹4.09
- Book value / share
- ₹32.53
- ROE
- 12.59%
- ROCE
- 16.24%
- ROA
- 8.1%
- Debt / equity
- 0.03x
- Dividend yield
- 1.91%
- EBITDA margin
- 8.56%
- 52-week range
- ₹66.72 – ₹107.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Anuh Pharma Ltd (ANUHPHR) reported revenue of ₹772 crore, net profit of ₹41 crore and earnings per share of ₹4.1. That compares with revenue of ₹662 crore and net profit of ₹47 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹202 crore and net profit ₹12 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 487 | 527 | 647 | 662 | 772 |
| Net profit (₹ cr) | 31 | 36 | 60 | 47 | 41 |
| EPS (₹) | 3.05 | 3.61 | 5.99 | 4.73 | 4.1 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.62% | 16.60% | 10.78% | 2.24% |
| Profit growth | 6.98% | 27.05% | 15.71% | -21.16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.8% of Anuh Pharma Ltd (ANUHPHR) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.01% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹789 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 1.2%, MICHAEL DSOUZA 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.8% | - | 0.01% | 0% | 28.2% |
| Mar 2026 | 71.8% | - | 0.05% | 0% | 28.2% |
| Dec 2025 | 71.82% | - | 0% | 0% | 28.18% |
| Sep 2025 | 71.82% | - | 0% | 0% | 28.18% |
| Jun 2025 | 69.92% | - | 0.04% | 0% | 30.08% |
| Mar 2025 | 69.92% | - | 0.04% | 0% | 30.08% |
| Dec 2024 | 69.92% | - | 0.02% | 0% | 30.08% |
| Sep 2024 | 69.92% | - | 0.02% | 0% | 30.08% |